DAIICHI SANKYO CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,556 JPY | -0.11% |
|
-1.89% | +17.67% |
| Apr. 10 | Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark | MT |
| Apr. 08 | AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
4,561
JPY
Average target price
5,620
JPY
Spread / Average Target
+23.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.67% | 56.7B | |
| +28.10% | 676B | |
| +24.27% | 559B | |
| -7.84% | 356B | |
| +14.71% | 320B | |
| +4.88% | 286B | |
| +2.62% | 213B | |
| +0.15% | 207B | |
| -9.41% | 199B | |
| -7.77% | 142B |
- Stock Market
- Equities
- 4568 Stock
- News Daiichi Sankyo Co., Ltd.
- Daiichi Sankyo Posts 8% Decline in Fiscal Nine-month Attributable Profit on Growing Expenses; Rejigs Management Structure
